Inhibrx Net Profit Margin 2020-2022 | INBX

Inhibrx net profit margin from 2020 to 2022. Net profit margin can be defined as net Income as a portion of total sales revenue.
Inhibrx Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2022-03-31 $0.01B $-0.09B -1175.00%
2021-12-31 $0.01B $-0.08B -1025.00%
2021-09-30 $0.01B $-0.08B -987.50%
2021-06-30 $0.01B $-0.08B -709.09%
2021-03-31 $0.01B $-0.08B -576.92%
2020-12-31 $0.01B $-0.08B -584.62%
2020-06-30 $0.01B $-0.06B -1160.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.452B $0.007B
Inhibrx Inc. is a clinical-stage biotechnology company. The company's pipeline is focused on oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00